Among all existing radionuclides, only a few are of interest for therapeutic applications and
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …

Recent Food and Drug Administration (FDA) approval of diagnostic and therapeutic
radiopharmaceuticals and concurrent miniaturization of particle accelerators leading to …

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic
applications. The imaging modalities positron emission tomography (PET) and single …

The high therapeutic effect of targeted radioisotope/radionuclide therapy (TRT) using α-
emitters, especially 225Ac, is attracting attention worldwide. However, the only 225Ac …

Targeted alpha therapy (TAT) is an area of research with rapidly increasing importance as
the emitted alpha particle has a significant effect on inducing cytotoxic effects on tumor cells …

Recent clinical success with metal-based radiopharmaceuticals has sparked an interest in
the potential of these drugs for personalized medicine. Although often overlooked, the …

A new method has been developed for the isolation of 223,224,225 Ra, in high yield and
purity, from a proton irradiated 232Th matrix. Herein we report an all-aqueous process using …

Background Actinium-225 is one of the most promising radionuclides for targeted alpha
therapy. Its limited availability significantly restricts clinical trials and potential applications of …

To develop the structural chemistry of radium, the halide compounds RaX2· H2O and RaX2·
2H2O (X–= Cl–and Br–) have been synthesized and characterized and serve as …

Radiopharmaceuticals are of growing interests in the development of theranostic agents and
personalized medicine because of their unique advantages. Diagnosis (via molecular …